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Summary  13 
Contrary to the classic model of PKA residing outside of the nucleus, we identify a nuclear 14 
signaling complex that consists of AKAP95, PKA, and PDE4D5 and show that it forms a 15 
functional cAMP signaling microdomain. Locally generated cAMP can accumulate within the 16 
vicinity of this complex; but when cAMP is generated at the plasma membrane, PDE4 serves as 17 
a local sink and PDE3 as a barrier to prevent accumulation of cAMP within the microdomain as 18 
a means of controlling activation of tethered nuclear PKA. 19 
 20 
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Introduction 22 
Protein kinase A (PKA) is a ubiquitous serine/threonine kinase involved in regulating 23 
multiple cellular processes. The PKA holoenzyme is a tetramer composed of a specific 24 
regulatory subunit isoform (RIα, RIβ, RIIα, or RIIβ) homodimer and two catalytic subunits, 25 
where each catalytic subunit is bound to a regulatory subunit in the dimer.  Activation of PKA 26 
occurs when cAMP binds the regulatory subunits, unleashing the active catalytic subunits.  In the 27 
classic understanding of the pathway, PKA signaling in the nucleus was thought to occur by 28 
activation of extranuclear PKA and diffusion of the catalytic subunit into the nucleus. Recent 29 
studies raise some questions as to whether or not the catalytic subunit of the PKA holoenzyme 30 
completely dissociates under physiological conditions (Smith et al., 2013, 2017). In the absence 31 
of translocated catalytic subunit, nuclear PKA signaling would need to be activated and regulated 32 
through alternative mechanisms. Our previous work suggests that a pool of activatable PKA 33 
holoenzyme exists in the nucleus, which can be activated by local cAMP generated in the cytosol 34 
or nucleus (Sample et al., 2012). Consistent with our findings, a recent study showed that high 35 
cAMP production resulting from synergistic actions of two GPCRs at the endosome can lead to 36 
the activation of nuclear PKA (Jean-Alphonse et al., 2016). However, the molecular components 37 
that localize this pool of PKA to the nucleus and the mechanism by which nuclear PKA is 38 
controlled locally remain to be identified. 39 
 AKAP95, a PKA RII binding protein, has been shown to localize to the nucleus. It has 40 
been associated with multiple functions, including chromatin condensation, RNA processing, 41 
and gene expression, and recently its upregulation has been correlated with increased cyclin D1 42 
and E1 expression in multiple types of cancer (Akileswaran et al., 2001; Arsenijevic et al., 2004, 43 
2006; Coghlan et al., 1994; Collas et al., 1999; Eide et al., 2002, 2003; Jiang et al., 2013; 44 
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Marstad et al., 2016; Zhao et al., 2015). We hypothesized that AKAP95 is a nuclear AKAP that 45 
anchors a specific pool of PKA holoenzyme within the nucleus.  46 
 47 
Results 48 
AKAP95 forms an endogenous complex with PKA and PDE 49 
To determine if AKAP95 forms a complex with PKA holoenzyme in the nucleus, we 50 
isolated nuclear proteins from HEK293T cells.  These nuclear lysates endogenously contain 51 
AKAP95 (Figure 1a).  The western blot results were further supported by immunofluorescence 52 
studies that detected AKAP95 in the nucleus (Figure 1b).  53 
To better characterize AKAP95 in the nucleus we performed fluorescence recovery after 54 
photobleaching (FRAP) experiments using GFP-tagged AKAP95.  On average, bleached areas 55 
showed a half recovery time of 25.7 ± 5.7 s (Supplemental Figure 1a) (N=11 cells). Based on 56 
these experiments, the majority of AKAP95 is mobile in the nucleus, with an average mobile 57 
fraction of 65.8 ± 11.2%. Interestingly, the observed AKAP95 puncta do not easily recover after 58 
photobleaching (Supplemental Figure 1b and 1c), suggesting that AKAP95 within these puncta 59 
is less mobile.    60 
In addition to AKAP95, endogenous RIIα and the catalytic subunit of the PKA 61 
holoenzyme (PKAcat) were also detected in the nucleus with nuclear fractionation followed by 62 
western blotting (Figure 1a) as well as immunofluorescence (Figure 1b). For RIIα and PKAcat, 63 
the nuclear staining is significantly less than the cytosolic staining, but is clearly above 64 
background (Supplemental Figure 1d, e). Previous studies suggest PDEs, specifically PDE4D 65 
isoforms, are directly involved in regulating nuclear PKA activity (Sample et al., 2012).  We 66 
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found evidence of PDE4D, specifically isoform PDE4D5, in the nucleus (Figure 1a) where 67 
PDE4D5 appears to form puncta (Figure 1b).     68 
To determine if the different components can form a complex in the nucleus, co-69 
immunoprecipitation studies on the nuclear lysates were performed. We first pulled down 70 
endogenous AKAP95 and found that it associates with endogenous PKA RIIα, PKAcat, and 71 
PDE4D5 (Figure 2a), which was further confirmed via reciprocal co-immunoprecipitation 72 
experiments in which we isolated RIIα or PDE4D5 and probed for the remaining components 73 
(Figure 2a). The signals were detected above the background from normal IgG controls, 74 
indicating the specificity of these interactions.  75 
Further support for the endogenous nuclear AKAP95 complex containing PKA and 76 
PDE4D comes from proximity ligation assay (PLA) experiments.  In these experiments 77 
complexes containing AKAP95 and RIIα were detected in intact, fixed cells (Figure 2b).  On 78 
average 1.65 ± 0.17 dots per nuclei (N=66 cells) were observed when measuring the AKAP95 79 
and RIIα interaction, which is significantly (p<0.0001) above the background signal observed 80 
with AKAP95 (Figure 2b) or RIIα (Supplementary Figure 1f-g) antibody alone (0.40 ± 0.09 81 
dots/nuclei, N=53 cells). Interestingly, although by immunofluorescence AKAP95 and RIIα are 82 
mainly detected in the nucleus and cytoplasm, respectively, PLA signal was observed in both the 83 
nucleus and cytoplasm (Supplemental Figure 1f-g).  Therefore, although there are limited 84 
amounts of AKAP95 and RIIα in specific subcellular compartments, they are still interacting in a 85 
significant way. PDE4D5 and AKAP95 were also observed to interact in the PLA experiments 86 
with an average of 3.80 ± 0.33 dots per nuclei (N=79 cells), which is significantly above the 87 
background signal produced by AKAP95 antibody alone (p<0.0001).  These results suggest that 88 
AKAP95 forms a complex with a resident pool of nuclear PKA, as well as PDE4D5.  89 
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 90 
The AKAP95 microdomain tightly regulates cAMP 91 
The identification of AKAP95 as a specific nuclear scaffold protein that binds to PKA 92 
and PDE allows us to directly test the hypothesis that PDEs co-anchored to the same AKAP 93 
complex help regulate the activation of this PKA pool by reducing local cAMP levels. First, we 94 
employed our previously developed mathematical model (Sample et al., 2012) to generate 95 
predictions of the localized cAMP dynamics within the nuclear AKAP compartment. This 96 
ordinary differential equation model was developed to test hypotheses for differences in cAMP 97 
dynamics between the cytosol and nucleus. We extended the model to include a FRET-based 98 
cAMP biosensor, ICUE3 (DiPilato and Zhang, 2009), in the nuclear AKAP compartment and 99 
used the previously developed parameters and initial conditions to predict how cAMP dynamics 100 
will differ between the general nucleus and AKAP95 compartments (Figure 3a, b). This model 101 
predicts that when a modest amount of cAMP is generated at the plasma membrane, the nucleus 102 
experiences increased cAMP accumulation, but the nuclear AKAP compartment does not. 103 
Furthermore, the model predicts that higher cAMP production can overcome PDE-mediated 104 
inhibition in the AKAP compartment, such that cAMP accumulates in both the general nucleus 105 
and nuclear AKAP compartments.    106 
To test these predictions experimentally, we targeted the FRET-based cAMP biosensor 107 
ICUE3 to AKAP95 to measure cAMP levels around AKAP95. This biosensor contains a cAMP 108 
binding domain sandwiched between a FRET pair and reports cAMP dynamics via changes in 109 
FRET. Targeting of this biosensor to AKAP95 was achieved using a chemically induced 110 
dimerization approach based on FK506 binding protein (FKBP) and FKBP-rapamycin binding 111 
domain (FRB), two proteins that bind specifically and tightly in the presence of rapamycin 112 
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(Banaszynski et al., 2005). This chemically inducible targeting system was chosen to avoid 113 
concerns of expressing a large fusion protein in the nuclear compartment. Although not utilized 114 
here, this system could offer some flexibility for experimental designs to evaluate nuclear and 115 
AKAP95 compartments in the same cells before and after rapamycin. FKBP was fused to the N-116 
terminus of nuclear-localized ICUE3 (FKBP-ICUE3-NLS), and FRB was fused to the C-117 
terminus of human AKAP95 (AKAP95-FRB) (Figure 3c and Supplemental Figure 2a). When 118 
HEK293T cells co-expressing FKBP-ICUE3-NLS and AKAP95-FRB were treated with 119 
rapamycin (100 nM), the diffuse pattern of reporter fluorescence became more punctate within 120 
the nucleus within minutes, indicating the translocation and recruitment of ICUE3 to AKAP95 121 
(Supplemental Figure 2b). HEK293T cells co-expressing these same two constructs were treated 122 
with rapamycin or DMSO (control) and harvested for co-immunoprecipitation experiments. 123 
Immunoprecipitation using anti-AKAP95 antibody followed by western blotting for GFP 124 
revealed that ICUE3 interacted with AKAP95 in cells treated with rapamycin, confirming the 125 
localization of the reporter to AKAP95 (Supplemental Figure 4c). To ensure that targeting 126 
ICUE3-NLS to AKAP95 did not affect the dynamic range of the reporter, the maximum 127 
responses of cells expressing either FKBP-ICUE3-NLS alone (N=39 cells) or both FKBP-128 
ICUE3-NLS and AKAP95-FRB (N=35 cells) were compared (Supplemental Figure 4d). In both 129 
cases, cells were treated with rapamycin, and the maximum response was stimulated by the 130 
addition of forskolin and IBMX to activate adenylyl cyclases and inhibit PDEs, respectively. 131 
After rapamycin treatment, the biosensor responded similarly to maximal cAMP stimulation 132 
regardless of AKAP95-FRB co-expression, indicating that the dynamic range of the biosensor is 133 
not affected by its localization to AKAP95.  134 
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To determine what effect the site of cAMP generation has on the cAMP levels within the 135 
AKAP95 compartment, we combined live-cell imaging using the localized cAMP biosensor with 136 
spatiotemporal manipulation of cAMP using soluble adenylyl cyclase (sAC), or SMICUS, which 137 
is a method previously developed to generate local pools of cAMP using subcellularly targeted 138 
sAC (Sample et al., 2012). sAC is pharmacologically distinct from the transmembrane adenylyl 139 
cyclase (tmAC).  Instead of being activated by GPCRs, it is activated by bicarbonate, ATP, or 140 
calcium (Zippin et al., 2013).  We can therefore use exogenously expressed mCherry-tagged sAC 141 
as a tool to generate cAMP in specific subcellular locations in a dose-dependent manner in 142 
HEK293T cells by the addition of sodium bicarbonate to the culture medium (Sample et al., 143 
2012). To this end, mCherry-tagged sAC was localized to either the plasma membrane (PM-144 
sAC) or the nucleus (sAC-NLS) (Figure 3c). PM-sAC generates cAMP at the plasma membrane, 145 
mimicking the production of cAMP by tmACs. HEK293T cells expressing PM-sAC and either 146 
FKBP-ICUE3-NLS alone for general nuclear targeting, or FKBP-ICUE3-NLS plus AKAP95-147 
FRB for AKAP95 targeting, were first treated with rapamycin (100 nM) (Figure 3d). Cells were 148 
then treated with a low dose (2.5 mM) of sodium bicarbonate to activate targeted sAC. Although 149 
cAMP production at the plasma membrane by sub-maximal sAC activation led to a clear 150 
response in the general nuclear compartment within 15 min, with an average emission ratio 151 
change of 11.3 ± 1.5% (N=39 cells), cAMP was not detected within the AKAP95 microdomain 152 
(mean emission ratio change -1.9 ± 0.8%, N=35 cells), suggesting that cAMP accumulation is 153 
tightly regulated in the area surrounding the AKAP95 complex, which represents a functional 154 
microdomain with distinct cAMP dynamics. Subsequent treatment with a saturating dose (15 155 
mM) of bicarbonate to maximally activate sAC resulted in increased FRET responses from both 156 
nuclear-localized and AKAP95-targeted ICUE3 (Figure 3d). Hence, although some cAMP 157 
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generated at the plasma membrane is able to diffuse into the nucleus, an added level of 158 
regulation limits the accumulation of cAMP within the AKAP95 microdomain. While there are 159 
differences in kinetics, these data qualitatively agree with the model predictions of an ablated 160 
cAMP response to the low stimulation condition in the AKAP95 compartment but a response to 161 
the high stimulation condition.   162 
Next, the cAMP responses within the AKAP95 compartment were compared when 163 
cAMP was generated at the plasma membrane or within the nucleus. When cAMP was generated 164 
in the nuclei of cells expressing sAC-NLS, even a low dose of sodium bicarbonate resulted in 165 
clear cAMP responses of 4.9 ± 0.8% within the AKAP95 microdomain (N=18 cells) compared to 166 
the lack of a response within the microdomain when cAMP was generated at the plasma 167 
membrane (-0.9 ± 0.8%, N=18 cells) (Figure 3e). Maximal activation of sAC in the nucleus or at 168 
the plasma membrane further increased the cAMP levels in the AKAP95 microdomain.  169 
These findings further support the existence of a functional microdomain that is distinct 170 
from the general nuclear environment in the immediate vicinity of AKAP95, where cAMP 171 
accumulation is limited unless cAMP is generated more locally or in excess levels from the 172 
plasma membrane. These results support the hypothesis that AKAP95 is able to create a distinct 173 
microdomain that limits cAMP concentrations, thereby providing a way to tune the activation 174 
threshold of the AKAP-anchored pool of PKA.   175 
 176 
PDE4 and PDE3 have distinct roles in regulating cAMP around AKAP95 177 
 To test the role of different PDE classes in regulating the microdomain, we used 178 
inhibitors specific to either PDE4 or PDE3. HEK293T cells expressing PM-sAC and rapamycin-179 
induced AKAP95-targeted ICUE3 were treated with rolipram (PDE4 inhibitor), milrinone 180 
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(PDE3 inhibitor) or vehicle control. Cells were subsequently treated with a low dose (2.5 mM), 181 
followed by a high dose (15 mM), of sodium bicarbonate to activate PM-sAC. 182 
The initial response after the addition of PDE inhibitor indicates the basal level of PDE activity 183 
at the microdomain. As shown in Figure 4a and b, cells treated with the PDE4 inhibitor rolipram 184 
(1 µM) exhibited an immediate increase in cAMP levels in the AKAP95 microdomain (9.4 ± 185 
1.9% emission ratio change, N=29 cells), suggesting that co-anchored PDE4 is basally active in 186 
restricting cAMP levels within the AKAP95 microdomain.  Subsequent addition of low-dose 187 
sodium bicarbonate following PDE4 inhibition further increased cAMP levels in the 188 
microdomain (10.0 ± 0.8%, N=29 cells), in sharp contrast to the limited response (4.9 ± 0.8%, 189 
N=39 cells) in the absence of any inhibitor (Figure 4c). Furthermore, a dominant-negative 190 
mutant of PDE4D5 (dnPDE4D5) was used as an alternative to global PDE4 inhibition by 191 
rolipram to more specifically investigate the role of PDE4D isoforms at the microdomain. This 192 
dominant-negative mutant is inactive and does not directly inhibit endogenous PDEs, but instead 193 
competes with and displaces them from binding to scaffolding proteins such as AKAP95 (Terrin 194 
et al., 2006).  We can therefore specifically interrogate the role of the scaffolded PDE4D5 in 195 
regulating the AKAP95 microdomain. HEK293T cells expressing AKAP95-targeted ICUE3, 196 
PM-sAC, and a dominant-negative mutant of PDE4D5 were treated with a low dose followed by 197 
a high dose of sodium bicarbonate. Cells expressing the mutant PDE4D5 exhibited a robust 198 
cAMP response to submaximal activation of PM-sAC (16.5 ± 1.9%, N=24 cells) compared with 199 
control cells that were not transfected with dominant-negative PDE4D5 (-1.9 ± 0.8%, N=35 200 
cells) (Figure 4d). These data suggest that basally active PDE4 restricts cAMP accumulation in 201 
the AKAP95 microdomain under both basal state and stimulated conditions.  202 
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In contrast, addition of the PDE3 inhibitor milrinone (10 µM) induced no response within 203 
the microdomain (2.0 ± 1.3%, N=19 cells) (Figure 4a-b), suggesting PDE3 does not play a role 204 
in controlling the basal level of cAMP within the AKAP95 microdomain. Interestingly, when 205 
PDE3 is inhibited with milrinone, submaximal activation of PM-sAC led to increased cAMP 206 
levels in the microdomain (13.4 ± 1.8%, N=19 cells) (Figure 4c), indicating that PDE3 plays a 207 
role in preventing low levels of plasma membrane-generated cAMP from accessing the 208 
microdomain.  209 
  210 
Discussion 211 
 Here we presented the identification of a nuclear signaling complex consisting of 212 
AKAP95, PKA, and PDE4D5. AKAP95 has previously been found to bind RIIα during mitosis 213 
after the nuclear envelope has dissolved (Collas et al., 1999).  Using both nuclear fractionation 214 
studies and whole-cell immunofluorescence experiments we demonstrate that nuclear AKAP95 215 
interacts with the regulatory subunit of PKA during interphase. These findings suggest that 216 
AKAP95 can anchor PKA in the nucleus irrespective of cell cycle stages. Previous studies have 217 
found that AKAP95 can associate with PDE4A in T-lymphocytes, but the functional role of 218 
anchored PDE4A was not tested (Asirvatham et al., 2004). Here we show that anchored PDE4D5 219 
plays a critical role in the functional cAMP signaling microdomain assembled by AKAP95.  220 
The roles played by different PDE isoforms are complex. Although it is widely accepted 221 
that cAMP diffusion is controlled and limited, the mechanisms underlying this 222 
compartmentalization are debated.  One model for cAMP regulation suggests the existence of a 223 
barrier to prevent cAMP diffusion away from a particular location (e.g., the plasma membrane). 224 
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An alternative model posits that PDEs concentrate in certain locations to prevent cAMP 225 
accumulation at those locations. Our results suggest these two mechanisms could co-exist in a 226 
PDE isoform-specific manner.  PDE4 isoforms are part of a complex with AKAP95 and create a 227 
local sink to limit the accumulation of cAMP within the AKAP95 microdomain.  Our data 228 
suggest that PDE3 is not a part of the AKAP95 complex but could act as a gate to prevent free 229 
diffusion of cAMP from the plasma membrane, the specific mechanisms and functional roles of 230 
which will be further investigated. The intricate interplay between these two different PDE 231 
isoforms and their effects on local signaling expands the concept of localized cAMP 232 
compartmentalization control to include proximate and distal PDE isoforms working in concert. 233 
cAMP is thus tightly regulated within this microdomain to prevent accidental nuclear PKA 234 
activation and reserve this pool of scaffolded PKA holoenzyme for transducing signals that 235 
generate specific, local sources of cAMP. 236 
What are the specific signals that can lead to the activation of this pool of nuclear PKA 237 
holoenzymes? Endogenous sAC has been shown to localize to subcellular locations such as the 238 
cytosol, nucleus, and mitochondria and respond to changes in bicarbonate, calcium, and ATP. 239 
sAC has been shown to act as a sensor for changes in pH and metabolism in different cell types 240 
(Tresguerres et al., 2010, 2011, Zippin et al., 2003, 2010, 2013) and could generate cAMP 241 
proximal to this pool of nuclear PKA. In addition, it has been demonstrated that endocytosed 242 
GPCRs continue signaling at the endosome and that this endosomal signaling elicits distinct 243 
transcriptional responses (Irannejad et al., 2013; Tsvetanova and von Zastrow, 2014).  cAMP 244 
generated at the endosome could provide a local source of cAMP that activates the nuclear PKA 245 
pool.  Supporting this hypothesis, Jean-Alphonse et al (Jean-Alphonse et al., 2016) recently 246 
showed that a synergistic effect between PTHR and β2-AR signaling induces pronounced 247 
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endosomal cAMP production that corresponds with activation of nuclear PKA and increased 248 
levels of phosphorylated CREB, a PKA substrate.  Given that GPCR internalization and 249 
endosomal cAMP production vary by receptor and ligand, the strength and extent of nuclear 250 
PKA activation by internalized GPCRs may be receptor specific. The tight regulation of cAMP, 251 
and by extension nuclear PKA, within the AKAP95 microdomain shown here provides a new 252 
example of signaling specificity arising from precise spatiotemporal control. 253 
 254 
Significance 255 
PKA signaling is integral to numerous cellular processes, and the spatiotemporal control 256 
of PKA is necessary for the regulation of its diverse downstream effects. The discovery and 257 
characterization of a nuclear PKA signaling microdomain further complicates the classical 258 
understanding of PKA signaling.  Instead of PKA activation occurring only in the cytosol, these 259 
findings suggest there exists a distinct nuclear pool of PKA that is reserved for sensing more 260 
“proximal” signals because the AKAP95 assembled nuclear microdomain specifically allows 261 
accumulation of locally generated cAMP. This study also demonstrates a clear example of 262 
synergistic effects of isoform-specific PDEs, where PDE4 is responsible for creating a local 263 
cAMP sink but also relies on more distal PDE3 to act as a gate and prevent the free diffusion of 264 
cAMP from overwhelming the local PDE4.  The studies discussed in this article expand our 265 
understanding of PKA signaling and regulation. Furthermore, the knowledge gained by 266 
understanding the regulation of nuclear PKA, a prototypic kinase and signaling molecule, can aid 267 
in developing better models for the study of spatiotemporal regulation of other signaling 268 
molecules. 269 
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Figure 1: AKAP95, PKA, and PDE are present in the nucleus 355 
a) Western blot images of whole-cell, non-nuclear, and nuclear HEK293T lysates reveal 356 
localization of AKAP95, PKARIIα, and PKAcat within the nucleus.  PDE4D5 is also detected in 357 
nuclear fractions, though PDE3B is not.  β-tubulin antibody staining shows a lack of cytosolic 358 
protein in the nuclear fraction, and probing for CREB provides a positive control for nuclear 359 
isolation. b) Representative images showing immunofluorescence staining of endogenous protein 360 
similarly detects the candidate proteins in the nucleus.  Scale bars, 10 µm (See Supplemental 361 
Figure 1 for quantification of nuclear localization of PKAcat and PKA RIIα).   362 
Figure 2: AKAP95 forms an endogenous complex with PKA and PDE 363 
a) Co-immunoprecipitation of nuclear fractions of HEK293T cells show interactions between 364 
AKAP95, RIIα and PDE4D5.  The left column shows the AKAP95 IP, including lanes for the 365 
nuclear lysate input, AKAP95 IP, and the control IP using normal IgG. PDE4D5 (indicated by 366 
arrow), RIIα, and PKAcat are detected in the AKAP95 pulldown.  The other components are also 367 
detected in immunprecipitates of RIIα or PDE4D5, shown in the right columns (western blot 368 
images representative of 2 or 3 repeated experiments). b) Proximity Ligation Assay (PLA) was 369 
performed with AKAP95 (N = 53 cells) and either RIIα (N = 66 cells) or PDE4D5 (N = 79 370 
cells).  Representative images are shown with quantification of nuclear PLA signal (average ± 371 
SEM). *** signifies p<0.0001. (See also Supplemental Figure 1).  The co-IP and PLA 372 
experiments indicate that RIIα, AKAP95, PDE4D5 form a complex within the nucleus of 373 
HEK293T cells. 374 
 Figure 3: The AKAP95 microdomain tightly regulates cAMP 375 
a) Based on a previous computational model for nuclear PKA activity, a new model was 376 
developed to predict cAMP levels in the AKAP microdomain and nucleus when cAMP is 377 
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generated at the plasma membrane in a dose-dependent manner using PM-sAC.  b) The model 378 
suggests different cAMP responses in the nucleus (orange) and AKAP microdomain (black) 379 
upon low-dose (LD, 2.5 mM) and high-dose (HD, 15 mM) NaHCO3 stimulation of cAMP 380 
production by PM-sAC. c) Using the FKBP/FRB dimerization system to localize ICUE3 to 381 
AKAP95, the model predictions were directly tested under three different experimental 382 
conditions: cAMP generated by PM-sAC and detected by the cAMP biosensor ICUE3 targeted 383 
to either i.) the nucleus or ii.) the AKAP95 microdomain of HEK293T cells, or iii.) cAMP 384 
generated in the nucleus by sAC-NLS and detected by AKAP95-targeted ICUE3. (See 385 
Supplemental Figure 3 for representative images). d) ICUE3 emission ratio (cyan/yellow) 386 
responses in the nucleus (orange, N=39 cells) and in the AKAP95 microdomain (black, N=35 387 
cells) stimulated by LD NaHCO3 (2.5 mM) followed by HD (15 mM) in HEK293T cells 388 
expressing PM-sAC. Shown is the average trace ± SEM. Comparison of the maximum responses 389 
to LD NaHCO3 shows a significant difference between the microdomain and nucleus (p<0.0001). 390 
e) ICUE3 emission ratio (cyan/yellow) responses in the AKAP95 microdomain stimulated by LD 391 
NaHCO3 (2.5 mM) followed by HD (15 mM) in HEK293T cells expressing PM-sAC (black, 392 
N=18 cells) or sAC-NLS (red, N=18 cells). The maximum response to LD NaHCO3 in the 393 
microdomain when cAMP is generated at the plasma membrane is significantly different 394 
compared with cAMP generated in the nucleus (inset, p<0.0001). 395 
Figure 4: PDE4 and PDE3 have distinct roles in regulating cAMP around AKAP95 396 
The effect of isoform-specific PDE inhibition was tested in the AKAP95 microdomain. Cells 397 
expressing AKAP95-targeted ICUE3 and PM-sAC were co-treated with PDE inhibitor and 398 
rapamycin (100 nM) and subsequently with NaHCO3 (LD, 2.5 mM; HD, 15 mM) to generate 399 
cAMP at the plasma membrane via PM-sAC. a) AKAP95-targeted ICUE3 emission ratio 400 
19 
 
(cyan/yellow) responses when cells were treated with the PDE4 inhibitor rolipram (1 µM) 401 
(purple, N=29 cells), the PDE3 inhibitor milrinone (10 µM) (blue, N=19 cells), or without 402 
inhibitor treatment (black, N=39 cells). Cells were additionally treated with a low dose (LD, 2.5 403 
mM) and subsequently a high dose (HD, 15 mM) of NaHCO3. b) The initial FRET response after 404 
inhibitor addition indicates basal PDE activity in the AKAP95 microdomain. The change in 405 
normalized ICUE3 emission ratio (cyan/yellow) is shown. There is a statistically significant 406 
response in cells treated with rolipram (p<0.0001) but not in cells treated with milrinone 407 
(p=0.1293). c) After low-dose NaHCO3 stimulation, a statistically significant response is 408 
observed in PDE4-inhibited cells (p<0.0001) and PDE3-inhibited cells (p=0.0002) compared to 409 
cells lacking inhibitor treatment. d) AKAP95-targeted ICUE3 emission ratio (cyan/yellow) 410 
responses in cells expressing dnPDE4D5 (purple, N=24 cells) or cells not expressing dominant 411 
negative PDE isoforms (black, N=35 cells). Cells were treated with LD (2.5 mM) followed by 412 
HD (15 mM) NaHCO3 to stimulate PM-sAC. e) LD PM-sAC stimulation induced statistically 413 
significant responses in cells expressing the dominant negative PDE4D5 compared to control 414 
cells (inset, p<0.0001).  415 
 416 
Methods 417 
CONTACT FOR REAGENT AND RESOURCE SHARING 418 
Further information and requests for resources and reagents should be directed to and will be 419 
fulfilled by the Lead Contact, Jin Zhang (jzhang32@ucsd.edu). 420 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 421 
Cell Culture 422 
20 
 
HEK293T cells (human embryonic kidney, female) were maintained in DMEM (10% (v/v) FBS 423 
and 1% (v/v) penicillin-streptomycin at 37°C with 5% CO2.  424 
METHOD DETAIL 425 
Nuclear Fractionation 426 
Sucrose-gradient centrifugation was used to isolate and collect nuclei. All steps were performed 427 
on ice. HEK293T cells were collected in DPBS and pelleted at 470  g for 10 min.  Gentle 428 
vortexing was used to resuspend the cell pellet in ice-cold Sucrose Buffer I (0.32 M), and cells 429 
were lysed by 15 strokes of a Dounce homogenizer B pestle. Lysates were gently mixed with 430 
Sucrose Buffer II (2.0 M) in a 50 mL tube.  The lysate-sucrose mix was layered on top of 431 
Sucrose Buffer II in a polyallomer SW 40.1 ultracentrifuge tube. Any space remaining in the 432 
tube was filled with Sucrose Buffer I.  A Beckman centrifuge with a SW41 Ti rotor was used to 433 
separate the nuclei at 30,000 rpm for 45 min, at 4°C.  Whole-cell, non-nuclear, and nuclear 434 
fractions were probed with antibodies against CREB (Cell Signaling 9197S) and β-tubulin (Cell 435 
Signaling 2146S) to ensure clean fractionation.  Antibodies used on fractionation samples: 436 
AKAP95 (R-146) (Santa Cruz, sc-10766), RIIα (H-12) (Santa Cruz, sc-137220), PKAcat (A-2) 437 
(Santa Cruz, sc-28315), PDE3B (H-300) (Santa Cruz, sc-20793), and PDE4D5 (gift from Dr. 438 
George Baillie). 439 
Co-Immunoprecipitation 440 
Protein A/G PLUS-Agarose beads (Santa Cruz sc-2003) or Protein A/G Magnetic Beads 441 
(bimake.com B23202) were equilibrated in Tris buffer.  Pre-clearing was achieved by incubation 442 
of agarose beads with 1 mg of nuclear protein and 5 g rabbit IgG (Santa Cruz sc-2027) for 1 h 443 
at 4°C to remove proteins that nonspecifically bind the beads or IgG. Pre-cleared lysate was 444 
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incubated with the immunoprecipitating antibody for 1 h at 4°C.  The lysate-antibody mix was 445 
incubated with agarose beads overnight.  After 4 washes with ice-cold DPBS, bound protein was 446 
eluted by boiling for 5 min in SDS sample buffer. Antibodies used for Co-IP: PKA IIα reg (C-447 
20) (sc-908), PDE4D5 (gift from Dr. George Baillie’s Lab), AKAP95 (R-146) (sc-10766), Clean 448 
Blot (Thermo Fisher Scientific 21230). 449 
Immunofluorescence Imaging 450 
Cells were rinsed in HBSS and then fixed in 4% PFA for 30 min, followed by permeabilization 451 
for 1 h at room temperature. Cells were then incubated overnight at 4°C or for 30 min at 37°C 452 
with primary antibody.  Alexa Fluor 488-conjugated and Alexa Fluor 568-conjugated secondary 453 
antibodies (Thermo Fisher Scientific A-11034, A-11001, A-11011, or A-11004) were incubated 454 
at room temperature for 1 h or 30 min at 37°C in the dark.  Cells were incubated with Hoescht 455 
33342 stain at room temperature for 30 min before imaging.  Cells were imaged on a Zeiss LSM 456 
880 Confocal with Airyscan processing using a 40x/1.2NA objective.  Images were acquired 457 
with the suggested settings using 405 nm, 488 nm, and 561 nm lasers.  Antibodies used for IF: 458 
AKAP95 (F-11) (Santa Cruz, sc-390335) or AKAP95 (R-146) (Santa Cruz, sc-10766), RIIα (C-459 
20) (Santa Cruz, sc-908), PKAcat (BDBiosciences Clone 5B cat#610980), PDE4D3 (gift from 460 
Dr. George Baillie), and PDE4D5 (gift from Dr. George Baillie). 461 
Proximity Ligation Assay 462 
PLA experiments were performed using the Duolink® in situ red starter kit for proximity 463 
ligation assays (Sigma Aldrich, DUO92101) according to the provided protocol. The only 464 
protocol modification was to extend the amplification time by 50 min.  Briefly, cells were fixed 465 
and permeabilized as in the immunofluorescence experiments before incubation with primary 466 
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antibody (same used for IF experiments), then with the provided secondary antibody (conjugated 467 
with nucleotides) for 30 min at 37°C each with washes after each step.  Ligation of the 468 
nucleotides and amplification of the strand occurred sequentially by incubating cells with first 469 
ligase then polymerase and detection solution.  PLA experiments with AKAP95 antibodies from 470 
different species were used as positive controls, and experiments with just one primary antibody 471 
(AKAP95) provided our negative control.  Images were acquired on a Zeiss LSM 880 Airyscan 472 
confocal as described above.  A cross section of the nucleus (3.6-5 µm) was acquired and the 473 
number of dots within that cross section counted both inside and outside the nucleus.   474 
Computational Modeling 475 
A previously developed computational model of compartmentalized cAMP and PKA dynamics 476 
in HEK293 cells (Sample et al., 2012) was modified to include ICUE in the nuclear AKAP 477 
compartment and evaluated in MATLAB (Mathworks).  Briefly, the “nucAKAP Model” is a 478 
compartmental ordinary differential equation (ODE) model that consists of plasma membrane, 479 
cytosol, nucleus and nuclear AKAP compartments. This model consists of equations describing 480 
cAMP production by adenylyl cyclases (both endogenous and over-expressed sAC), cAMP 481 
degradation by PDEs, and cAMP activation of PKA. Additionally, the cAMP biosensor ICUE 482 
and PKA biosensor AKAR were included in all the compartments except for the nuclear AKAP 483 
compartment. We extended this “nucAKAP Model” to include ICUE in the nuclear AKAP 484 
compartment by making the following modifications.  485 
A new second-order reaction of cAMP binding to ICUE in the nuclear AKAP 486 
compartment: 487 
𝑑𝐼𝐶𝑈𝐸𝑐𝐴𝐾𝐴𝑃
𝑑𝑡
= 𝑘𝑓,𝐼𝐶𝑈𝐸 ∙ 𝑐𝐴𝑀𝑃𝐴𝐾𝐴𝑃 ∙ 𝐼𝐶𝑈𝐸𝐴𝐾𝐴𝑃 − 𝑘𝑟,𝐼𝐶𝑈𝐸 ∙ 𝐼𝐶𝑈𝐸𝑐𝐴𝐾𝐴𝑃 
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And an additional conservation of mass equation for total ICUE in the nuclear AKAP 488 
compartment: 489 
𝐼𝐶𝑈𝐸𝐴𝐾𝐴𝑃 = 𝐼𝐶𝑈𝐸𝑡𝑜𝑡𝐴𝐾𝐴𝑃 − 𝐼𝐶𝑈𝐸𝑐𝐴𝐾𝐴𝑃 
And finally, the conservation of mass for free cAMP in the nuclear AKAP compartment was 490 
updated to account for the cAMP that is bound to ICUE.  491 
𝑐𝐴𝑀𝑃𝐴𝐾𝐴𝑃
= 𝑐𝐴𝑀𝑃𝑡𝑜𝑡𝐴𝐾𝐴𝑃 − 𝑅𝑎𝐶𝐴𝐾𝐴𝑃 − 𝑅𝑏𝐶𝐴𝐾𝐴𝑃 − 2𝑅𝑎𝑏𝐶𝐴𝐾𝐴𝑃 − 𝑅𝑎𝐴𝐾𝐴𝑃
− 𝑅𝑏𝐴𝐾𝐴𝑃 − 2𝑅𝑎𝑏𝐴𝐾𝐴𝑃 − 𝐼𝐶𝑈𝐸𝑐𝐴𝐾𝐴𝑃 
No new kinetic parameters were introduced, as the rates of cAMP association and dissociation 492 
with ICUE are assumed to be consistent across compartments. Total ICUE in the AKAP 493 
compartment, 𝐼𝐶𝑈𝐸𝑡𝑜𝑡𝐴𝐾𝐴𝑃, was assumed to be equal to the total amount of PKA in the AKAP 494 
compartment, which assumes that each AKAP has both PKA and ICUE bound to it. All other 495 
equations and parameters are as described in the supplement of Sample et al 2012 (Sample et al., 496 
2012). 497 
This model was run using the initial conditions from the published model and allowed to 498 
equilibrate by running for 10
9
 s. Using the simulated plasma membrane-targeted sAC built into 499 
the model (𝐸𝑠𝐴𝐶,𝑝𝑚,𝑏𝑎𝑠𝑎𝑙 = 1.663 ∙ 10
−1 mM/s), cAMP production was stimulated with a low 500 
dose of NaHCO3 (increase 𝐸𝑠𝐴𝐶,𝑝𝑚,𝑏𝑎𝑠𝑎𝑙 by 1𝑥1.726 ∙ 10
−1) for 15 min and then subjected to a 501 
high dose of NaHCO3 (increase 𝐸𝑠𝐴𝐶,𝑝𝑚,𝑏𝑎𝑠𝑎𝑙 by 6𝑥1.726 ∙ 10
−1) for another 15 min.  502 
Cloning 503 
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Full-length human AKAP95 was kindly provided by Dr. John D. Scott (University of 504 
Washington). FKBP and FRB constructs were kindly provided by Dr. Takanari Inoue (Johns 505 
Hopkins University). FRB or GFP were tagged to the C-terminus of AKAP95 using BamHI and 506 
EcoRI or NotI restriction sites.  FKBP with a flexible linker was added to the N-terminus of 507 
ICUE3 (DiPilato and Zhang, 2009) using HindIII and BamHI restriction sites. 508 
Live-cell Imaging 509 
HEK293T cells were transfected with Lipofectamine 2000 (Invitrogen) when cells were 50-60% 510 
confluent and imaged 16-24 h later. Cells were washed twice with and maintained in Hank’s 511 
balanced salt solution buffer (HBSS). Cells were imaged at room temperature. 512 
FRAP Imaging 513 
FRAP experiments were performed on a Leica TCS SP8 confocal microscope using its 514 
associated FRAP software, a 63x/1.4NA objective, and a DD488/552 beamsplitter.  A total of 5 515 
images were acquired before bleaching a rectangular cross-section or circular area of the nucleus 516 
with 25% laser power.  Post-bleaching images were acquired every 5 or 10 s for at least 5 min.  517 
Images were analyzed using the Jython script found at: 518 
http://imagej.net/Analyze_FRAP_movies_with_a_Jython_script.   519 
FRET Imaging 520 
Prior to imaging, cells were equilibrated in HBSS for 10 min in a CO2-independent incubator. 521 
Cells were treated with NaHCO3 (J.T. Baker, purity=100%), which induced a small change in 522 
FRET for the FKBP-tagged biosensor with or without co-expression of AKAP95-FRB (seen in 523 
Figure 3), forskolin (Calbiochem, purity ≥99% by HPLC), IBMX (Sigma, purity ≥98% by TLC), 524 
rolipram (Alexis, purity ≥98% by TLC), or milrinone (Alexis, purity ≥97% by TLC) as 525 
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indicated.  Cells were imaged on a Zeiss Axio Observer Z1 microscope equipped with a 40x/1.3 526 
NA objective and Photometrics Evolve 512 EMCCD, using METAFLUOR 7.7 software 527 
(Molecular Devices) to control dual-emission-ratio imaging acquisition every 30 s.  A 420DF20 528 
excitation filter, a 450DRLP dichroic mirror, and two emission filters (475DF40 for CFP and 529 
535DF25 for YFP) alternated by a Lambda 10-2 filter-changer (Sutter instruments) were used for 530 
the FRET measurements.  The microscope settings for RFP (sAC) fluorescence acquisition were 531 
as follows: 555DF25 excitation filter, 568rdc dichroic mirror, and 650DF100 emission filter.  532 
Exposure times for all channels ranged from 50-500 ms.  Emission intensities of individual cells 533 
were background-subtracted, and the ratio between the CFP and FRET channel was normalized 534 
to the timepoint just before addition of low-dose NaHCO3 (t = 0 min). Because overexpressed 535 
sAC has some basal activity prior to stimulation, the starting FRET ratio for AKAP95-localized 536 
ICUE3 was higher in cells expressing sAC-NLS compared to PM-sAC.  Therefore, a moderate 537 
range of overlap in starting ratios between these two experiments was determined, and cells were 538 
selected for comparison based on starting ratio within this range to control for basal activity 539 
differences. On the other hand, the expression of PM-sAC was controlled to be within a defined 540 
range, and this range was held constant between different experimental conditions; cells outside 541 
this range were excluded from analysis.  542 
 543 
QUANTIFICATION AND STATISTICAL ANALYSIS 544 
2-3 biological replicates were done for Co-IP and PLA experiments, and at least 3 biological 545 
replicates performed for all other experiments. Unpaired two-tailed t-tests with Welch’s 546 
correction were used for statistical analyses, done in Graphpad Prism. *** indicates a p-547 
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value<0.0001. N values, as indicated in figure legends and the main text, represent number of 548 
cells. All error bars indicate standard error. 549 
KEY RESOURCES TABLE 550 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Goat anti-mouse Alexa Fluor 488-conjugate Thermo Fisher 
Scientific 
Cat# A-11001, 
RRID:AB_253406
9 
Goat anti-rabbit Alexa Fluor 568-conjugate Thermo Fisher 
Scientific 
Cat# A-11011, 
RRID:AB_143157 
Goat anti-mouse Alexa Fluor 568-conjugate Thermo Fisher 
Scientific 
Cat# A-11004, 
RRID:AB_253407
2 
Goat anti-rabbit Alexa Fluor 488-conjugate Thermo Fisher 
Scientific 
Cat# A-11034, 
RRID:AB_257621
7 
PKA RIIa (C-20) monoclonal rabbit Santa Cruz 
Biotechnology 
Cat# sc-908, 
RRID:AB_632214 
PKA RIIa (H-12) monoclonal mouse Santa Cruz 
Biotechnology 
Cat# sc-137220, 
RRID:AB_226860
8 
AKAP95 (R-146) polyclonal rabbit Santa Cruz 
Biotechnology 
Cat# sc-10766, 
RRID:AB_222606
0 
AKAP95 (F-11) monoclonal mouse Santa Cruz 
Biotechnology 
Cat# sc- 390335 
PKAcat (A-2) monoclonal rabbit Santa Cruz 
Biotechnology 
Cat# sc-28315, 
RRID:AB_628136 
PKAcat (Clone 5B) monoclonal mouse BD Biosciences Cat# 610980, 
RRID:AB_398293 
CREB monoclonal rabbit Cell Signaling 
Technology 
 Cat# 9197, 
RRID:AB_331277 
β-Tubulin polyclonal rabbit Cell Signaling 
Technology 
 Cat# 2146, 
RRID:AB_221054
5 
PDE3B polyclonal rabbit Santa Cruz 
Biotechnology 
Cat# sc-20793, 
RRID:AB_228357
9 
PDE4D3 rabbit Dr. George Baillie n/a 
PDE4D5 rabbit Dr. George Baillie n/a 
Clean Blot Thermo Fisher 
Scientific 
Cat# 21230 
Bacterial and Virus Strains  
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E. coli DH5α Thermo Fisher 
Scientific 
Cat# 18265017 
Biological Samples   
Chemicals, Peptides, and Recombinant Proteins   
BamHI Thermo Fisher 
Scientific 
Cat# FD0054 
EcoRI Thermo Fisher 
Scientific 
Cat# FD0274 
NotI Thermo Fisher 
Scientific 
Cat# FD0594 
HindIII Thermo Fisher 
Scientific 
Cat# FD0504 
NaHCO3 J.T. Baker Cat# 3506-01 
forskolin Calbiochem Cat# 344270 
milrinone Alexis Cat# ALX-270-
083-M005 
IBMX Sigma Cat# I5879 
rolipram Alexis Cat# ALX-270-
119 
Critical Commercial Assays   
Duolink® in situ red starter kit Sigma DUO92101 
Deposited Data   
Experimental Models: Cell Lines   
HEK293T ATCC CRL-11268 
Experimental Models: Organisms/Strains   
Oligonucleotides   
Recombinant DNA   
Full-length human AKAP95 Dr. John D. Scott 
(University of 
Washington) 
 
FRB Dr. Takanari Inoue 
(Johns Hopkins 
University) 
 
FKBP Dr. Takanari Inoue 
(Johns Hopkins 
University) 
 
Software and Algorithms   
FRAP Analysis Jython Script http://imagej.net/An
alyze_FRAP_movie
s_with_a_Jython_scr
ipt 
 
ImageJ NIH imagej.nih.gov/ij/ 
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MATLAB Mathworks https://www.math
works.com/product
s/matlab.html 
Prism 5 GraphPad Software www.graphpad.co
m 
METAFLUOR 7.7 Molecular Devices www.molecularde
vices.com 
Leica Application Suite, Advanced Fluorescence 
FRAP wizard 
Leica www.leica-
microsystems.com 
Other   
Protein A/G Magnetic Beads for IP Bimake.com Cat# B23202 
Protein A/G PLUS-agarose beads Santa Cruz 
Biotechnology 
Cat# sc-2003, 
RRID:AB_102014
00 
 551 
Figure1 Click here to access/download;Figure;Figure1.tif
Figure2 Click here to access/download;Figure;Figure2.tif
Figure3 Click here to access/download;Figure;Figure3.tif
Figure4 Click here to access/download;Figure;Figure4.tif
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Figure S1. Related to Figure 1: Characterizing AKAP95 and its complex with PKA RIIα and PDE4D5 in the 
nucleus.
Fluorescence Recovery After Photobleaching (FRAP) analysis was performed to assess the mobility of AKAP95 within 
the nucleus. Shown here are representative cells expressing AKAP95-GFP directly before bleaching, directly after 
bleaching, and 5 min after bleaching. Scale bars are 10 µm.  Also shown are the recovery curves indicating fluorescence 
in photobleached ROIs (rectangle for a and b and circle for c), both experimental (single points) and fitted (solid line). 
Three qualitatively different observed populations of AKAP95 were recorded, and representative cells are shown here.  a) 
Diffuse AKAP95 readily diffuses throughout the nucleus, and has a mobile fraction on average of 65.8% (N=11 cells). b) 
AKAP95 puncta were also observed (white arrow). Bleaching a cross section of the nucleus that contains AKAP95 
puncta shows that while AKAP95 diffuses into the bleached area, the puncta do not re-form readily.  This observation is 
quantitatively supported by a decrease in the mobile fraction as determined by the recovery curve for this cell. c) In a 
separate example, AKAP95 puncta are observed in an area absent of diffuse AKAP95 (white arrow). When AKAP95 
within this area of the nucleus is photobleached, it does not recover within the imaging time, suggesting that AKAP95 in 
that location is less mobile. d) Representative images from Figure 1 of immunofluorescence staining in HEK293T cells 
are shown. A rectangular crosssection of a representative cell was selected and the corresponding normalized intensity 
across the selection graphed.  Shown is the protein of interest (PKA RIIα, or PKAcat) in green, AKAP95 in magenta, and 
nuclei (based on Hoescht stain) as a shaded blue area in the graph.  While the nuclear signal is lower than the cytosolic 
signal, it is still distinctly above background. e) The difference between background (extracellular ROI) and nuclear 
(nuclear ROI based on Hoescht stain) signal is quantified, and for both PKAcat and RIIα there is an approximately 35-
fold increase in nuclear signal over background.  This difference is statistically significant (p<0.0001 for PKAcat and 
p=0.0004 for PKA RIIα) and supports the western blot data in Figure 1 showing the existence of these proteins in the 
nucleus endogenously.  More detailed quantification for the PLA experiments is also shown. The data from Figure 1 are 
shown as well as a positive control PLA experiment using two AKAP95 antibodies.  Shown are f) representative images, 
scale bar 10 µm, and g) a bar graph (average ± SEM) of the quantified nuclear signal (dots/nuclei). The extra-nuclear 
signal is also quantified and represented in a bar graph (average ± SEM).  These results show that AKAP95 forms a 
nuclear complex with PDE4D5 and PKA RIIα in the nucleus, but that it can also form complexes in the cytosol.
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Figure S2. Related to Figure 2 and 3: Targeting ICUE3 to AKAP95
a) A schematic of targeting ICUE3 to AKAP95 is shown, repeated from Figure 2 for clarity.  FKBP 
was fused to the N-terminus of ICUE3-NLS and FRB to the C-terminus of AKAP95.  b) Upon addition 
of rapamycin there is a clear redistribution of ICUE3 within the nucleus, indicating that it is targeted to 
AKAP95. This redistribution is quantitatively shown with a line scan. c) Co-IP of HEK293T cells also 
demonstrates ICUE3 (detected with a GFP antibody) localization to AKAP95 in the presence of 
rapamycin.  d) The maximum responses of ICUE3 in the nucleus or targeted to AKAP95 were 
compared to ensure localization to AKAP95 did not inherently limit the dynamic range of the FRET 
response.  There is no difference (p=0.3788) in their response to forskolin (50 µM) and IBMX (100 
µM) co-treatment (to stimulate production of cAMP and inhibit PDEs, respectively).
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Figure S3. Related to Figure 2 and 3: Measuring cAMP around AKAP95
a) Representative images are shown to indicate localization of the biosensor and sAC in the different experimental 
conditions discussed in Figure 2. sAC is represented in magenta, and ICUE3 (either FKBP-ICUE3-NLS alone or 
AKAP95 localized ICUE3) in green.  The FKBP-ICUE3-NLS samples do not express AKAP95-FRB but were still 
treated with rapamycin. b-e) Individual cell traces with the average (bold) are shown for the different experiments 
presented in Figures 2 and 3.
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